<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/staar-surgical-nasdaqstaa-rating-lowered-to-hold-at-valuengine.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T11:46:47+00:00"/>
    <meta property="og:title" content="STAAR Surgical (NASDAQ:STAA) Rating Lowered to Hold at ValuEngine"/>
    <meta property="og:description" content="STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, ValuEngine reports. Several other research analysts also recently issued reports on STAA. Zacks Investment Research downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in […]"/>
  </head>
  <body>
    <article>
      <h1>STAAR Surgical (NASDAQ:STAA) Rating Lowered to Hold at ValuEngine</h1>
      <address><time datetime="2019-11-21T11:46:47+00:00">21 Nov 2019, 11:46</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/staar-surgical-company-logo.GIF"/>
      </figure>
      <p>STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=STAA">ValuEngine</a> from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, <a href="https://www.valuengine.com/">ValuEngine</a> reports.</p>
      <p>Several other research analysts also recently issued reports on STAA. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Canaccord Genuity upped their price target on shares of STAAR Surgical from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Finally, BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $41.67.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/STAA/price-target/">NASDAQ STAA</a> traded up $0.51 during midday trading on Tuesday, reaching $36.18. The company’s stock had a trading volume of 4,184 shares, compared to its average volume of 406,184. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.96 and a current ratio of 5.50. STAAR Surgical has a fifty-two week low of $21.70 and a fifty-two week high of $41.65. The business’s 50 day moving average price is $30.14 and its two-hundred day moving average price is $29.09. The company has a market cap of $1.57 billion, a P/E ratio of 129.21 and a beta of 2.34.</p>
      <p>STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Wednesday, October 30th. The medical instruments supplier reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. STAAR Surgical had a net margin of 6.15% and a return on equity of 13.84%. The business had revenue of $39.06 million during the quarter, compared to the consensus estimate of $37.50 million. Sell-side analysts forecast that STAAR Surgical will post 0.25 earnings per share for the current fiscal year.</p>
      <p>In related news, CFO Deborah J. Andrews sold 4,167 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $34.68, for a total value of $144,511.56. Following the sale, the chief financial officer now owns 32,101 shares of the company’s stock, valued at $1,113,262.68. The sale was disclosed in a legal filing with the SEC, which is accessible through <a href="https://www.sec.gov/Archives/edgar/data/718937/000120919119056725/xslF345X03/doc4.xml">the SEC website</a>. Also, CTO Keith Holliday sold 2,100 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $35.00, for a total transaction of $73,500.00. Following the completion of the sale, the chief technology officer now directly owns 28,764 shares in the company, valued at approximately $1,006,740. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/718937/000120919119055495/xslF345X03/doc4.xml">here</a>. Insiders have sold 7,850 shares of company stock valued at $273,306 over the last quarter. Company insiders own 4.30% of the company’s stock.</p>
      <p>Several institutional investors have recently modified their holdings of the stock. BBVA USA Bancshares Inc. bought a new stake in shares of STAAR Surgical in the third quarter worth $276,000. Russell Investments Group Ltd. bought a new stake in STAAR Surgical during the third quarter valued at $66,000. California Public Employees Retirement System boosted its position in STAAR Surgical by 50.1% during the third quarter. California Public Employees Retirement System now owns 84,000 shares of the medical instruments supplier’s stock valued at $2,166,000 after acquiring an additional 28,024 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in STAAR Surgical during the third quarter valued at $398,000. Finally, State of New Jersey Common Pension Fund D bought a new stake in STAAR Surgical during the third quarter valued at $1,949,000. 90.33% of the stock is currently owned by institutional investors.</p>
      <p>
        <b>About STAAR Surgical</b>
      </p>
      <p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/book-value-equity-per-share-bvps/">Book Value Per Share – BVPS</a></p>
      <p>To view ValuEngine’s full report, visit <a href="https://www.valuengine.com/rep/order_report?pid=64&amp;srchfor=STAA">ValuEngine’s official website</a>.</p>
    </article>
  </body>
</html>